Table 4.
Proportion of azithromycin-resistant (AzmR) and macrolide-inducible clindamycin resistant (iMLSB) S. aureus isolates over time and between treatment arms
| Survey | Total | Resistant (%) | Crude OR (95% CI) | p-value | Adjusted ORa (95% CI) | p-value |
|---|---|---|---|---|---|---|
| Overtime | ||||||
| AzmR | ||||||
| CSS-1 | 102 | 37 (36.3) | 1 | 1 | ||
| CSS-2 | 161 | 142 (88.2) | 13.13 (7.67–22.48) | <0.001 | 13.01 (7.77–21.80) | <0.001 |
| CSS-3 | 30 | 25 (83.3) | 8.78 (1.11–69.25) | 0.039 | 8.56 (1.03–71.34) | 0.047 |
| iMLSB | ||||||
| CSS-1 | 102 | 24 (23.5) | 1 | 1 | ||
| CSS-2 | 161 | 128 (79.5) | 12.61 (8.33–19.09) | <0.001 | 12.52 (7.90–19.85) | <0.001 |
| CSS-3 | 30 | 20 (66.7) | 6.50 (3.14–13.44) | <0.001 | 6.39 (3.22–12.66) | <0.001 |
| Between treatment arms | ||||||
| AzmR | ||||||
| 1× | 25 | 6 (24.0) | 1 | 1 | ||
| 3× | 30 | 25 (83.3) | 15.83 (1.97–127.01) | 0.009 | 15.88 (1.99–126.54) | 0.009 |
| iMLSB | ||||||
| 1× | 25 | 3 (12.0) | 1 | 1 | ||
| 3× | 30 | 20 (66.7) | 14.67 (2.43–88.41) | 0.003 | 18.83 (3.22–110.05) | 0.001 |
aadjusted for age and gender